News
FEMY
0.4380
+29.85%
0.1007
Weekly Report: what happened at FEMY last week (0518-0522)?
Weekly Report · 12h ago
Weekly Report: what happened at FEMY last week (0511-0515)?
Weekly Report · 05/18 09:30
Femasys updates corporate presentation on women’s health portfolio
TipRanks · 05/13 22:35
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA)
TipRanks · 05/13 17:00
Femasys announces CE Mark approval for FemHSG Catheter
TipRanks · 05/13 14:46
Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners
Benzinga · 05/13 13:05
FEMASYS EXPANDS FERTILITY CARE PORTFOLIO IN EUROPE WITH CE MARK APPROVAL FOR FEMHSG™ CATHETER
Reuters · 05/13 13:01
Femasys wins CE Mark approval for FemHSG catheter in Europe
PUBT · 05/13 13:00
Lake Street Remains a Buy on Femasys (FEMY)
TipRanks · 05/12 13:16
Weekly Report: what happened at FEMY last week (0504-0508)?
Weekly Report · 05/11 09:28
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns
TipRanks · 05/10 06:00
Femasys Q1 sales rise on FemBloc demand
Reuters · 05/08 20:26
FEMASYS INC. Q1 EPS USD 0
Reuters · 05/08 20:15
Femasys swings to Q1 profit of 846,100; sales rise 24.5% to 424,889
PUBT · 05/08 20:07
FEMASYS ANNOUNCES FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2026 AND PROVIDES CORPORATE UPDATE
Reuters · 05/08 20:05
Press Release: Femasys Announces Financial -2-
Dow Jones · 05/08 20:05
*Femasys 1Q EPS 0c >FEMY
Dow Jones · 05/08 20:05
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Dow Jones · 05/08 20:05
*Femasys 1Q Sales $424,889 >FEMY
Dow Jones · 05/08 20:05
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Barchart · 05/08 15:05
More
Webull provides a variety of real-time FEMY stock news. You can receive the latest news about FEMASYS INC through multiple platforms. This information may help you make smarter investment decisions.
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.